Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) shares gapped up before the market opened on Friday . The stock had previously closed at $0.23, but opened at $0.24. Actinium Pharmaceuticals shares last traded at $0.26, with a volume of 2,885,776 shares.
Several analysts have weighed in on the company. Zacks Investment Research lowered Actinium Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, January 20th. Maxim Group restated a “buy” rating and issued a $1.50 price target on shares of Actinium Pharmaceuticals in a research report on Wednesday, December 11th.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04).
Hedge funds have recently bought and sold shares of the stock. UBS Group AG boosted its stake in shares of Actinium Pharmaceuticals by 119.7% during the 4th quarter. UBS Group AG now owns 174,990 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 95,333 shares during the last quarter. Virtu Financial LLC grew its holdings in shares of Actinium Pharmaceuticals by 295.0% during the fourth quarter. Virtu Financial LLC now owns 407,794 shares of the biotechnology company’s stock worth $89,000 after buying an additional 304,549 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Actinium Pharmaceuticals by 97.8% during the fourth quarter. Renaissance Technologies LLC now owns 990,343 shares of the biotechnology company’s stock worth $216,000 after buying an additional 489,770 shares in the last quarter. Finally, Sabby Management LLC raised its position in shares of Actinium Pharmaceuticals by 5.4% in the third quarter. Sabby Management LLC now owns 8,797,509 shares of the biotechnology company’s stock valued at $2,023,000 after buying an additional 453,793 shares during the last quarter.
About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.
Further Reading: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.